Management of challenging cases of patients with cancer-associated thrombosis including recurrent thrombosis and bleeding: guidance from the SSC of the ISTH
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Management of challenging cases of patients with cancer-associated thrombosis including recurrent thrombosis and bleeding: guidance from the SSC of the ISTH
Authors
Keywords
-
Journal
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
Volume 11, Issue 9, Pages 1760-1765
Publisher
Wiley
Online
2013-06-28
DOI
10.1111/jth.12338
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
- (2013) Gary H. Lyman et al. JOURNAL OF CLINICAL ONCOLOGY
- Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients
- (2013) Alexander T. Cohen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism
- (2013) Sam Schulman et al. NEW ENGLAND JOURNAL OF MEDICINE
- How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch
- (2012) S. Schulman et al. BLOOD
- Antithrombotic Therapy for VTE Disease
- (2012) Clive Kearon et al. CHEST
- Development of a Clinical Prediction Rule for Risk Stratification of Recurrent Venous Thromboembolism in Patients With Cancer-Associated Venous Thromboembolism
- (2012) Martha L. Louzada et al. CIRCULATION
- Duration of anticoagulant therapy after a first episode of an unprovoked pulmonary embolus or deep vein thrombosis: guidance from the SSC of the ISTH
- (2012) T. BAGLIN et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer
- (2012) D. FARGE et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
- (2012) NEW ENGLAND JOURNAL OF MEDICINE
- Apixaban for Extended Treatment of Venous Thromboembolism
- (2012) Giancarlo Agnelli et al. NEW ENGLAND JOURNAL OF MEDICINE
- Investigating the benefit of adding a vena cava filter to anticoagulation with fondaparinux sodium in patients with cancer and venous thromboembolism in a prospective randomized clinical trial
- (2012) Myra F. Barginear et al. SUPPORTIVE CARE IN CANCER
- Treatment of established thrombotic events in patients with cancer
- (2012) Agnes Y.Y. Lee THROMBOSIS RESEARCH
- Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines
- (2011) M. Mandala et al. ANNALS OF ONCOLOGY
- Thrombosis in Cancer: An Update on Prevention, Treatment, and Survival Benefits of Anticoagulants
- (2011) A. Y. Y. Lee Hematology-American Society of Hematology Education Program
- Prevalence of Fracture and Fragment Embolization of Bard Retrievable Vena Cava Filters and Clinical Implications Including Cardiac Perforation and Tamponade
- (2010) William Nicholson et al. ARCHIVES OF INTERNAL MEDICINE
- Oral Rivaroxaban for Symptomatic Venous Thromboembolism
- (2010) NEW ENGLAND JOURNAL OF MEDICINE
- Long-Term Use of Different Doses of Low-Molecular-Weight Heparin Versus Vitamin K Antagonists in the Treatment of Venous Thromboembolism
- (2009) A. Romera-Villegas et al. ANNALS OF VASCULAR SURGERY
- Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients
- (2009) M. CARRIER et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
- (2009) Sam Schulman et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More